Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical trials and therapy

S Gauthier1

  • 1Department of Neurology and Neurosurgery, McGill University, Verdun, Quebec, Canada.

Current Opinion in Neurology
|December 16, 1998
PubMed
Summary
This summary is machine-generated.

Cholinesterase inhibitors offer short-term benefits for Alzheimer's disease cognition. Future Alzheimer's trials should focus on clinical milestones to assess disease-delaying treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Observance of antifibrotic treatment in the French OPALE support program for patients with pulmonary fibrosis].

Revue des maladies respiratoires·2026
Same author

Drying Spring Accelerates Transitions Toward Pyrogenic Vegetation in Eastern Boreal North America.

Ecology letters·2025
Same author

Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force.

The journal of prevention of Alzheimer's disease·2024
Same author

Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials.

The journal of prevention of Alzheimer's disease..·2024
Same author

Clinical Correlates of the PET-based Braak Staging Framework in Alzheimer's Disease.

The journal of prevention of Alzheimer's disease·2024
Same author

CTAD Task Force Paper: Neuropsychiatric Symptoms in AD: Clinical Trials Targeting Mild Behavioral Impairment: A Report from the International CTAD Task Force.

The journal of prevention of Alzheimer's disease·2024
Same journal

Movement disorders and Parkinson's disease: collaborative and interdisciplinary research to advance understanding of neural circuit dysfunction, pathophysiology, and care: new horizons in technology, neuroimaging, neurophysiology, and genetics toward personalized medicine.

Current opinion in neurology·2026
Same journal

Editorial introduction.

Current opinion in neurology·2026
Same journal

Multimodal mapping of balance dysfunction in Parkinson's disease: a consensus roadmap for research and intervention.

Current opinion in neurology·2026
Same journal

Tourette syndrome: brain neurophysiology, circuit dysfunction, and neuromodulation across invasive and noninvasive approaches.

Current opinion in neurology·2026
Same journal

Dystonia: from phenotypes to genetics and therapeutic advances.

Current opinion in neurology·2026
Same journal

What can we learn from eye movements in movement disorders and Parkinson's disease?

Current opinion in neurology·2026
See all related articles

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Cholinesterase inhibitors are approved for Alzheimer's disease treatment.
  • Their efficacy is primarily demonstrated for short-term cognitive and global clinical improvement.

Purpose of the Study:

  • To evaluate the role of cholinesterase inhibitors in Alzheimer's disease.
  • To explore the utility of time-to-event outcomes in clinical trials for Alzheimer's disease.

Main Methods:

  • Review of parallel-group studies on cholinesterase inhibitors in Alzheimer's disease.
  • Discussion of noncognitive outcomes and clinical milestone assessments.

Main Results:

  • Established efficacy of cholinesterase inhibitors for short-term cognitive and global outcomes.

Related Experiment Videos

  • Noncognitive outcomes require further investigation.

    • Conclusions:

    • Cholinesterase inhibitors provide limited short-term benefits in Alzheimer's disease.
    • Time-to-clinical-milestone designs may be more suitable for evaluating disease-modifying therapies.